Physician profile
Judith M Andreano
NPI 1316939911
$151,833.80
in general payments reported to CMS, 2019-2025
41 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $15K · 2021: $17K · 2022: $12K · 2023: $17K · 2024: $32K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $16K · Travel and Lodging: $1,997 · Consulting Fee: $1,840 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,037.50 |
| Food and Beverage | $16,394.87 |
| Travel and Lodging | $1,997.20 |
| Consulting Fee | $1,840.00 |
| Education | $414.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89,014.90 | 2020-2025 | Otezla, Otezla, Enbrel |
| Almirall LLC | $18,077.84 | 2019-2022 | |
| Celgene Corporation | $10,099.03 | 2019 | |
| Abbvie INC. | $3,776.75 | 2019-2025 | Skyrizi, Rinvoq |
| Journey Medical Corporation | $3,262.80 | 2019-2024 | |
| Janssen Biotech, INC. | $3,261.70 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Dermavant Sciences, INC. | $2,685.98 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $2,488.06 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,185.03 | 2023-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $2,097.79 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $2,029.46 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,479.03 | 2019-2025 | |
| Lilly USA, LLC | $1,403.85 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,229.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,184.00 | 2020-2025 | Dupixent, Libtayo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $854.13 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Ucb, INC. | $840.75 | 2019-2025 | Bimzelx, Cimzia |
| Epi Health, LLC | $760.52 | 2019-2022 | |
| Pfizer INC. | $739.46 | 2019-2025 | |
| Incyte Corporation | $671.33 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $614.91 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $609.14 | 2019-2021 | |
| Promius Pharma LLC | $542.26 | 2019 | |
| Verrica Pharmaceuticals INC. | $381.55 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $304.92 | 2019-2025 | Adbry, Anzupgo |
| Organon LLC | $295.63 | 2025 | Vtama, Hadlima |
| Vyne Pharmaceuticals INC. | $219.58 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $147.94 | 2019-2024 | Tremfya |
| Dermira, INC. | $135.12 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $103.79 | 2019-2025 | |
| Biofrontera INC. | $70.90 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Cipher Pharmaceuticals US LLC | $45.48 | 2025 | Natroba, Spinosad |
| Paratek Pharmaceuticals, INC. | $39.51 | 2024-2025 | Nuzyra |
| Organogenesis INC. | $33.33 | 2025 | Puraply Wound Matrix |
| Allergan, INC. | $28.92 | 2021-2022 | |
| Lnhc, INC | $26.87 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $25.44 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.67 | 2019 | |
| Botanix Sb INC | $17.11 | 2025 | Sofdra |
| Encore Dermatology INC. | $16.68 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Andreano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.